HomeProductsBioactive CompoundsImmunology & InflammationCXCRElubrixin
Chemical structure of CAS 688763-64-6

Elubrixin

In Stock•Starting at $88 for 1 mg•Purity ≥ 98%
CAS No.688763-64-6
MDL No.N/A
MFC17H17Cl2FN4O4S
MW463.30
InChI KeyYQYFEGTYCUQBEI-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mg98%$88In Stock
5 mg98%$405In Stock
10 mg98%$415In Stock
25 mg98%$983In Stock
50 mg98%$1326In Stock
100 mg98%$2121In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.688763-64-6
Product NameElubrixin

Biological Targets

CXCR2

Associated Conditions

chronic obstructive pulmonary disease·ulcerative colitis·cystic fibrosis
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Pharmacological reviews • Vol. 66, Issue 1 • 2014
PMID: 24218476PMC: PMC3880466DOI: 10.1124/pr.113.007724

Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society • Vol. 12, Issue 3 • 2013
PMID: 22995323DOI: 10.1016/j.jcf.2012.08.016

SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans.

British journal of clinical pharmacology • Vol. 72, Issue 2 • 2011
PMID: 21426372PMC: PMC3162658DOI: 10.1111/j.1365-2125.2011.03968.x

Documentation

Similar Products